FDA Approves Casgevy for Young Children With Sickle Cell Disease
SILVER SPRING, Maryland, July 1, 2026 The U.S. Food and Drug Administration (FDA) has granted supplemental approval for Casgevy...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SILVER SPRING, Maryland, July 1, 2026 The U.S. Food and Drug Administration (FDA) has granted supplemental approval for Casgevy...
BOSTON, July 1, 2026 Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the expanded...
